JP6281991B2 - ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法 - Google Patents
ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法 Download PDFInfo
- Publication number
- JP6281991B2 JP6281991B2 JP2016512786A JP2016512786A JP6281991B2 JP 6281991 B2 JP6281991 B2 JP 6281991B2 JP 2016512786 A JP2016512786 A JP 2016512786A JP 2016512786 A JP2016512786 A JP 2016512786A JP 6281991 B2 JP6281991 B2 JP 6281991B2
- Authority
- JP
- Japan
- Prior art keywords
- cnh
- carbon nanohorn
- boron
- plpeg
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims description 34
- 229910052799 carbon Inorganic materials 0.000 title claims description 32
- 239000002116 nanohorn Substances 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 150000001639 boron compounds Chemical class 0.000 title description 19
- 229910052796 boron Inorganic materials 0.000 claims description 33
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 32
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 24
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 12
- 235000019152 folic acid Nutrition 0.000 claims description 12
- 239000011724 folic acid Substances 0.000 claims description 12
- 229960000304 folic acid Drugs 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- JBANFLSTOJPTFW-UHFFFAOYSA-N azane;boron Chemical compound [B].N JBANFLSTOJPTFW-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 229910052582 BN Inorganic materials 0.000 claims description 5
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002041 carbon nanotube Substances 0.000 description 5
- 229910021393 carbon nanotube Inorganic materials 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009616 inductively coupled plasma Methods 0.000 description 4
- 230000036326 tumor accumulation Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000619 electron energy-loss spectrum Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005411 Van der Waals force Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000001241 arc-discharge method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005430 electron energy loss spectroscopy Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 239000011964 heteropoly acid Substances 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Carbon And Carbon Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014082154 | 2014-04-11 | ||
| JP2014082154 | 2014-04-11 | ||
| JP2014215682 | 2014-10-22 | ||
| JP2014215682 | 2014-10-22 | ||
| JP2015011605 | 2015-01-23 | ||
| JP2015011605 | 2015-01-23 | ||
| PCT/JP2015/061209 WO2015156385A1 (fr) | 2014-04-11 | 2015-04-10 | Nanocornet de carbone pour encapsulation et transport de composé de bore sur une paroi externe, et procédé de production de nanocornet de carbone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2015156385A1 JPWO2015156385A1 (ja) | 2017-04-13 |
| JP6281991B2 true JP6281991B2 (ja) | 2018-02-21 |
Family
ID=54287956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512786A Expired - Fee Related JP6281991B2 (ja) | 2014-04-11 | 2015-04-10 | ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6281991B2 (fr) |
| WO (1) | WO2015156385A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107224580B (zh) * | 2016-03-25 | 2020-10-16 | 南京中硼联康医疗科技有限公司 | 类α-氨基酸三氟化硼化物在硼中子俘获治疗中的应用 |
| WO2017162093A1 (fr) * | 2016-03-25 | 2017-09-28 | 南京中硼联康医疗科技有限公司 | Système de traitement par capture de neutrons de bore et mise en oeuvre d'un trifluorure de bore de type acide alpha-aminé dans la fabrication d'un médicament destiné au traitement de tumeurs |
| JP6844773B2 (ja) * | 2017-03-01 | 2021-03-17 | 国立大学法人 岡山大学 | 細胞内導入機能を有するホウ素を含むデンドリマー |
| EP4353680A1 (fr) * | 2021-06-11 | 2024-04-17 | Kyoto University | Nanoparticule modifiée en surface |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003250391A1 (en) * | 2002-07-22 | 2004-02-09 | Psimei Pharmaceuticals Plc | Conjugates of biocompatible polymers with nuclide activation therapy reagents |
| JP2004256370A (ja) * | 2003-02-27 | 2004-09-16 | Toshihiro Yamase | ホウ素原子含有ヘテロポリ酸及びホウ素化合物 |
| JP2005053904A (ja) * | 2003-07-24 | 2005-03-03 | Ideal Star Inc | フラーレン類、及び抗癌治療剤 |
| JP2013057577A (ja) * | 2011-09-08 | 2013-03-28 | Shinshu Univ | 放射線を用いる識別方法及びこれに用いる識別材料 |
-
2015
- 2015-04-10 WO PCT/JP2015/061209 patent/WO2015156385A1/fr active Application Filing
- 2015-04-10 JP JP2016512786A patent/JP6281991B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015156385A1 (fr) | 2015-10-15 |
| JPWO2015156385A1 (ja) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geng et al. | Carbon dot-passivated black phosphorus nanosheet hybrids for synergistic cancer therapy in the NIR-II window | |
| Wang et al. | Cyanine-assisted exfoliation of covalent organic frameworks in nanocomposites for highly efficient chemo-photothermal tumor therapy | |
| Qi et al. | Inorganic–organic hybrid nanomaterials for photothermal antibacterial therapy | |
| Li et al. | Technical synthesis and biomedical applications of graphene quantum dots | |
| Fan et al. | Group IV nanoparticles: synthesis, properties, and biological applications | |
| Hu et al. | Engineering of a novel pluronic F127/graphene nanohybrid for pH responsive drug delivery | |
| Karousis et al. | Current progress on the chemical modification of carbon nanotubes | |
| Akhavan et al. | Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy | |
| Makharza et al. | Graphene oxide-based drug delivery vehicles: functionalization, characterization, and cytotoxicity evaluation | |
| Hu et al. | Low-dimensional nanomaterials for antibacterial applications | |
| Gao et al. | Biomedical applications of 2D monoelemental materials formed by group VA and VIA: a concise review | |
| Zheng et al. | Multifunctional graphene quantum dots-conjugated titanate nanoflowers for fluorescence-trackable targeted drug delivery | |
| JP6281991B2 (ja) | ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法 | |
| Liu et al. | Synthesis of mesoporous silica/reduced graphene oxide sandwich-like sheets with enlarged and “funneling” mesochannels | |
| Wang et al. | Mesoporous carbon nanoshells for high hydrophobic drug loading, multimodal optical imaging, controlled drug release, and synergistic therapy | |
| Zhang et al. | Graphene oxide and adenosine triphosphate as a source for functionalized carbon dots with applications in pH-triggered drug delivery and cell imaging | |
| Yallappa et al. | Synthesis of a biocompatible nanoporous carbon and its conjugation with florescent dye for cellular imaging and targeted drug delivery to cancer cells | |
| Ren et al. | Multifunctional hierarchical mesoporous silica and black phosphorus nanohybrids as chemo-photothermal synergistic agents for enhanced cancer therapy | |
| Duong et al. | Biocompatible chitosan-functionalized upconverting nanocomposites | |
| Ranasinghe et al. | Engineered 2D materials for optical bioimaging and path toward therapy and tissue engineering | |
| Zhang et al. | Aptamer-mediated nanocomposites of semiconductor quantum dots and graphene oxide as well as their applications in intracellular imaging and targeted drug delivery | |
| Sui et al. | Incorporation of cisplatin into PEG-wrapped ultrapurified large-inner-diameter MWCNTs for enhanced loading efficiency and release profile | |
| Tufano et al. | Methods to scale down graphene oxide size and size implication in anti-cancer applications | |
| Yang et al. | Synthesis of boron carbonitride nanosheets using for delivering paclitaxel and their antitumor activity | |
| Xie et al. | Fullerene covalent passivation of black phosphorus nanosheets toward enhanced near-infrared-II photothermal therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161017 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20161213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6281991 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |